Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 5/20 | 0.84 |
| ▸ | RUNX1 | Q01196 | 12/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179114 | 0.91 | CBFB (0.70) | CBFBRUNX1TRPV1DGAT1 | |
| SCHEMBL19831268 | 0.91 | CBFB (0.70) | CBFBRUNX1TRPV1DGAT1 | |
| SCHEMBL19831263 | 0.91 | CBFB (0.70) | CBFBRUNX1TRPV1DGAT1 | |
| SCHEMBL24245908 | 0.90 | CBFB (0.69) | CBFBRUNX1TRPV1DGAT1P2RY6 | |
| SCHEMBL22878769 | 0.90 | CBFB (0.69) | CBFBRUNX1TRPV1 | |
| SCHEMBL24950162 | 0.88 | CBFB (0.65) | CBFBRUNX1TRPV1DGAT1P2RY6 | |
| SCHEMBL126350 | 0.88 | CBFB (0.66) | CBFBRUNX1TRPV1DGAT1 | |
| SCHEMBL179105 | 0.88 | CBFB (0.65) | CBFBRUNX1NPC1RAB9A | |
| SCHEMBL19831265 | 0.87 | CBFB (0.65) | CBFBRUNX1TRPV1DGAT1 | |
| SCHEMBL26159466 | 0.85 | CBFB (0.61) | CBFBRUNX1TRPV1DGAT1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3670509-B1 | INHIBITORS OF INV(16) LEUKEMIA | UNIV VIRGINIA PATENT FOUNDATION (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-3670509-A1 | INHIBITORS OF INV(16) LEUKEMIA | The University of Virginia Patent Foundation (US) | 2020-06-24 | — | — | EP | disclosed |
| US-9926290-B2 | Inhibitors of INV(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2016-04-07 | — | — | US | disclosed |
| US-9221764-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8748618-B2 | Inhibitors of inv(16) leukemia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2010132684-A9 | INHIBITORS OF INV(16) LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059003-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CBFB 3/4885RUNX1 10/4885TRPV1 4546/4885 |
| US-20140243331-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CBFB 3/4885RUNX1 10/4885TRPV1 4526/4885 |
| US-20160096820-A1 | INHIBITORS OF INV(16) LEUKEMIA | FLI1, MCL1, CBFB | CBFB 3/4885RUNX1 10/4885TRPV1 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.